

Attorney Docket No.: 3556.224-US

7

A/

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## **EXPRESS MAIL CERTIFICATE**

Box Patent Application Assistant Commissioner for Patents Washington, DC 20231

Re: U.S. Patent Application for

"Proteins with Changed Epitopes and Methods for the Production

Thereof"

Applicant: Uffe Loevborg

Sir:

Express Mail Label No. EM165549275US

Date of Deposit April 7, 1998

I hereby certify that the following attached paper(s) or fee

- 1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
- 2. Patent Application
- 3. Formal Drawings
- 4. Executed Combined Declaration and Power of Attorney
- 5. Preliminary Amendment

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Miriam Kelly

(Name of person mailing paper(s) or fee)

(Signature of person mailing paper(s) or fee)

Mailing Address:

Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10017 (212) 867-0123

Attorney Docket No.: 3556.224-US PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## **FILING UNDER 37 C.F.R. 1.53(b)**

Box Patent Application Assistant Commissioner for Patents Washington, DC 20231

Express Mail Label No. EM165549275US Date of Deposit April 7, 1998

Sir:

This is a request for filing a divisional application under 37 C.F.R. 1.53(b) of

Applicant(s): Uffe Loevborg

Title: Proteins with Changed Epitopes and Methods for the Production

Thereof

38 pages of specification 3 sheets of drawings

2 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee: \$790.00

Total Claims:  $16 - 20 = 0 \times 22 = 0 \times$ 

Independent Claims:  $1 - 3 = 0 \times 82 = $0$ 

Total Fee: \$790.00

Priority of application serial no. EP 90610072.2 filed on December 5, 1990 is claimed under 35 U.S.C. 119. A certified copy thereof was filed in the prior application.

The benefit of application serial nos. 08/050,172 filed on April 16, 1993, 08/346,590 filed on November 29, 1994, respectively, in the U.S. and PCT/DK91/00382 filed on December 5, 1991 via the PCT is claimed under 35 U.S.C. 120.

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$790, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: April 7, 1998

Carol E. Rozek, Reg. No. 36,993 Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10174-6401 (212) 867-0123